Barbed arrow-like structure membrane with ultra-high rectification coefficient enables ultra-fast, highly-sensitive lateral-flow assay of cTnI.
Juanhua LiYiren LiuTianyu WuZihan XiaoJianhang DuHongrui LiangCuiping ZhouJian-Hua ZhouPublished in: Nature communications (2024)
Acute myocardial infarction (AMI) has become a public health disease threatening public life safety due to its high mortality. The lateral-flow assay (LFA) of a typical cardiac biomarker, troponin I (cTnI), is essential for the timely warnings of AMI. However, it is a challenge to achieve an ultra-fast and highly-sensitive assay for cTnI (hs-cTnI) using current LFA, due to the limited performance of chromatographic membranes. Here, we propose a barbed arrow-like structure membrane (BAS Mem), which enables the unidirectional, fast flow and low-residual of liquid. The liquid is rectified through the forces generated by the sidewalls of the barbed arrow-like grooves. The rectification coefficient of liquid flow on BAS Mem is 14.5 (highest to date). Using BAS Mem to replace the conventional chromatographic membrane, we prepare batches of lateral-flow strips and achieve LFA of cTnI within 240 s, with a limit of detection of 1.97 ng mL -1 . The lateral-flow strips exhibit a specificity of 100%, a sensitivity of 93.3% in detecting 25 samples of suspected AMI patients. The lateral-flow strips show great performance in providing reliable results for clinical diagnosis, with the potential to provide early warnings for AMI.
Keyphrases
- acute myocardial infarction
- left ventricular
- public health
- percutaneous coronary intervention
- high throughput
- high resolution
- end stage renal disease
- ionic liquid
- ejection fraction
- newly diagnosed
- healthcare
- simultaneous determination
- chronic kidney disease
- heart failure
- peritoneal dialysis
- prognostic factors
- cardiovascular disease
- cardiovascular events
- label free
- coronary artery disease
- risk assessment
- magnetic resonance imaging
- single cell
- emergency department
- magnetic resonance
- patient reported outcomes
- global health
- adverse drug
- contrast enhanced
- patient reported
- real time pcr